Find more items about these cancer types:

Kidney (Renal Cell)

Axitinib Showed Two-Month Advantage To Sorafenib

(00:02:16) Elsevier Global Medical News, 2011 Jun 6

Overall, 3.4% of the patients had to discontinue this investigational drug, due to side effects.

See related videos to:
ASCO 2011

Related Link:

News Article: Axitinib Extends Progression-Free Survival in Kidney Cancer Trial »

Copyright © 2010 International Medical News Group
Subscribe Now »

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Most Viewed Video

Video Blog: Dr. Axel Grothey on CRC Studies at ECCO-ESMO 2011
2011 Oct 17
OncologySTAT Video Network

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration